First clinical results for radioligand therapy using the alpha emitter Ac-225-PSMA I&T in patients with end stage mCRPC

Conclusions: In this small cohort Ac-225-PSMA I&T RLT showed antitumor effect in end stage mCRPC even after failure of Lu-177 PSMA-ligand therapy in more than 40%. Grade 3/4 hematological side effects in 50% of patients and Grade 1-2 xerostomia in 11/12 patients indicate moderate tolerability in this heavily pretreated end stage patient group. These results are comparable to data for Ac225 PSMA-617 after failure of Lu-177 therapy.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Zacherl, M., Gildehaus, F. J., Gosewisch, A., Boening, G., Bartenstein, P., Todica, A., Ilhan, H. Tags: Prostate: PSMA radioligand therapy Source Type: research